On the path toward development of an optimal anti-SARS-CoV-2 sulfated glycan with significant S-protein binding and potent SARS-CoV-2 inhibitory effect, but having minimal anticoagulant side effects, IbSF provides a good lead for future research to develop an effective and selective new anti-COVID-19 agent. The gene discussed is PROS1; the disease is COVID-19.